Business
Personalis to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
MENLO PARK, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team
About this update from Personalis, Inc.
[{"type":"text","content":" MENLO PARK, Calif.--(BUSINESS WIRE)--\nPersonalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 15, 2022 at 2:00 p.m. Eastern Time.\n\nThe webcast link is available only for those who are attending the BTIG conference.\n\nAbout Personalis, Inc.\n\nPersonalis, Inc. is a leader in advanced cancer genomics for enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. To enable cancer sequencing, the Personalis Clinical Laboratory was built with a focus on clinical accuracy, quality, big data, scale, and efficiency. The laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).\nView source version on businesswire.com: https://www.businesswire.com/news/home/20220201006054/en/\n\nInvestor Relations Contact:\nCaroline Corner\[email protected]\n415-202-5678\n\nMedia Contact:\nJennifer Havlek\[email protected]\nwww.personalis.com\n650-752-1300\n\nSource: Personalis, Inc.","length":4082,"tagName":"div"}]